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Mantel cell lymphoma is one of the small B-cell non-Hodgkin’s lymphomas and usually involves lymph
nodes, bone marrow, spleen, liver, gastrointestinal tract, and Waldeyer’s ring, but rarely skin and orbit. A
53-year-old man presented skin nodules and plaques on the head, trunk, and lower extremities for half
a month, and the left periorbital region swelled 4 days ago. Serum calcium and lactate dehydrogenase
were increased to 3.12 mmol/L (normal 2.03e2.65 mmol/L) and 853 U/L (normal 71e231 U/L), respec-
tively. Histopathologic examination of the skin nodule revealed tumor cells inﬁltrated nodular distri-
bution in the dermis and subcutaneous tissue. Immunophenotyping of the abnormal lymphocytes
indicated positive reactions for L26, CD79a, Bcl-2, Cyclin D1, and Ki-67 (>80%), but negative for CD5,
CD21, CD23, CD38, CD3, CD10, UCHL-1, TdT, MPO, CD30, ALK, CD117, and CD34. Fluorescence in situ
hybridization analysis with the CCND1/IGH probe revealed a fusion signal on the abnormal lymphocytes.
The ﬁnal diagnosis was a rare case of blastoid mantle cell lymphoma involving skin and orbit with
hypercalcemia. Following the R-Hyper-CVAD treatment plan, the patient achieved a quick and excellent
recovery on the 6th day. Unfortunately, the patient eventually died of pneumonia one month later.
Copyright  2012, Taiwanese Dermatological Association.
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Mantel cell lymphoma (MCL) is a rare B-cell non-Hodgkin’s
lymphoma with a poor long-term prognosis. Skin involvement
occurs in only 2e6% of all cases of MCL, but is seen in 17% of stage IV
patients.1 It is important for the dermatologist to realize andmaster
the primary clinic presentation and pathologic features of the skin,
as these will help in early and correct diagnosis of the disease. We
report a case of blastoid mantle cell lymphoma involving skin and
orbit with hypercalcemia.
Case report
A 53-year-oldmanpresentedwith dark purple nodules and plaques
on the left temporal region, right palpebra frontalis (Figure 1A),
abdomen (Figure 1B), and bilateral lower extremities for ½ month,
and the left periorbital region swelled 4 days prior to his initial visit, The First Afﬁliated Hospital
510080, China. Tel.: þ86 20
per.
iwanese Dermatological Associatioto our department of dermatology. Physical examination revealed
signiﬁcant superﬁcial lymph node enlargement and splenomegaly.
Serum calcium and lactate dehydrogenase (LDH) were increased to
3.12 mmol/L (normal 2.03e2.65 mmol/L) and 853 U/L (normal 71e
231 U/L), respectively. The agarose gel electrophoresis showed
a monoclonal immunoglobulin IgM (k chain). Positron emission
tomography computed tomography scan showed multiple areas of
abnormal uptake in lymph nodes, back wall of pharynx, and spleen.
Bone marrow aspirate revealed active myeloid proliferation and
42% of lymphoblast was observed. Flow cytometry displayed CD20
(93.7%), CD22 (91.0%), human leukocyte antigen (HLA)-DR (99.3%),
CD19 (82.9%), CD79a (95.2%), cytoplasma K (98.0%), CD2 (51.5%),
and CD15 (32.7%). CD13, CD56, CD41, CD61, and CD42a were all
negative. Histopathologic examination of the skin nodule in the
neck revealed atypical lymphoid cells (Figure 2B) inﬁltrated
nodular distribution in the dermis and subcutaneous tissue
(Figure 2A). Immunophenotype of the abnormal lymphocytes
indicated positive reactions for L26 (Figure 2C), CD79a, Bcl-2, Cyclin
D1 (Figure 2D), Mum-1 (partly), and Ki-67 (>80%), but negative for
CD5 (Figure 2D), CD21, CD23, CD38, CD3, CD10, Bcl-6, UCHL-1, TdT,
MPO, CD30, ALK, CD117, and CD34. The translocation t(11:14)
juxtaposes the cyclin D1 gene (CCND1) at 11q13 to the immuno-
globulin heavy chain (IgH) promoter locus at chromosome 14q32,n. Published by Elsevier Taiwan LLC. All rights reserved.
Figure 1 Prior to (left) and after (right) treatment. (A) Orbit and (B) abdomen.
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lymphomas, and can be found in virtually all cases of MCL by using
ﬂuorescence in situ hybridization (FISH) techniques. The patient’s
result of FISH analysis with the CCND1/IGH probe revealed a yellow
fusion signal on the abnormal lymphocytes (Figure 3). Based on the
cytological characterization of the inﬁltrated tumor cells (mono-
morphic sheets of small- to medium-sized blasts with ﬁnely
dispersed chromatin mimicking lymphoblastic lymphoma) and
clinical data, the diagnosis was blastoid MCL (stage IVB) with
hypercalcemia. R-Hyper-CVAD chemotherapy was delivered: rit-
uximab 700 mg d0 (only 50 mg was used as the patient did not
tolerate it well because of chilling and fever), cyclophosphamide
1.5 g q12h d1e3, vincristine 2 mg d4 and d11, theprubicin (THP)
90 mg d4, and dexamethasone 40 mg d1e4 and d11e14. Three days
later, serum calcium became normal. On the 6th day, the lesions on
the temporal site of the head, abdomen, and bilateral lower
extremities had signiﬁcantly diminished. Edema around the orbit
ameliorated, and the patient could open his eyes (Figure 1). Unfor-
tunately, the patient eventually died of pneumonia 1 month later.
Discussion
MCL is mostly found among adults with a median age ranging from
60 to 65 years and a high male-to-female ratio.2 At presentation,
there is involvement of lymph nodes (75%), spleen (massive
splenomegaly in 45e60% of cases), liver (hepatomegaly in 35%),
Waldeyer’s ring, bone marrow (>60%), blood (13e77%), andextranodal sites, especially the gastrointestinal tract. Less
commonly, skin, lung, breast, soft tissue, salivary glands, and orbit
are involved.3 According to cytological characterization, MCL could
be divided into four types: classical, blastoid, small cell, and pleo-
morphic. The cells of MCL are usually positive for CD5, CD43, CD19,
CD20, CD22, CD79a, and CD79b, and negative for CD3, CD23, CD11c,
CD10, and Bcl-6. Especially, MCL characteristically display nuclear
positivity for cyclin D1 (bcl-1), which is strongly associated with all
variants of this lymphoma, including the small group of CD5-
negative cases.
Because skin lesions are visible, many cases are ﬁrstly diagnosed
by the dermatologist. Among 18 cases of MCL reviewed by Canpolat
et al,4 with cutaneous inﬁltration at the ﬁrst clinical visit, dermal
lesions were found in 11 patients on trunk and face, in three on
upper and lower limbs, and in two on lower limbs. Most of the
lesions were nodules, and a few were maculapapules and purple
plaques. Sen et al5 reported ﬁve cases of MCL involving skin, among
which four had blastoid cytological feature without the expression
of CD5. Evidence claimed that MCL with cutaneous inﬁltration had
a universal involvement and pessimistic prognosis. Most of such
patients died as a result of the progression of disease or ineffec-
tiveness of combined chemotherapy, with a median survival period
of 33 months after being diagnosed.6 This case conformed to the
record of documents in terms of cutaneous lesion, cytological
characterization, and immunohistochemistry feature.
B-cell lymphoma is less frequently associated with hypercal-
cemia. Hypercalcemia is also strongly associated with an aggressive
Figure 2 Histopathologic features. (A) Tumor cells inﬁltrated nodular distribution (hematoxylineeosin stain, original magniﬁcation 40). (B) Atypical lymphoid cells (hematoxyline
eosin stain, original magniﬁcation 400), immunopathological features. (C) L26 stains (original magniﬁcation 400). (D) Cyclin D1 stains (original magniﬁcation 400).
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lymphoma. Hattori et al7 demonstrated that macrophage inﬂam-
matory protein-1a (MIP-1a), an osteoclast-activating factor
produced by mantle lymphoma cells, may contribute to the
development of hypercalcemia. It likely acts through receptor-
activator of nuclear-factor kappa B ligand expression in tumor
cells and/or stroma cells, as indicated in multiple myeloma and
adult T-cell leukemia/lymphoma. Furthermore, MIP-1a is alsoFigure 3 Fluorescence in situ hybridization. Yellow fusinvolved in the development of an aggressive phenotype onMCL by
stimulating proliferation of these lymphoma cells.
Now,MCL is generally treatedmore aggressively than in the past.
Unfortunately, with the current treatments, including very aggres-
sive approaches, MCL remains an incurable disease. Age >65 years
and elevated b2-microglobulin and LDH levels were adverse prog-
nostic factors, with 5% of toxic deaths due to neutropenic sepsis and
secondarymyelodysplastic syndrome or acute leukemia, with a riskion signal on the abnormal lymphocytes (arrow).
J. Li et al. / Dermatologica Sinica 31 (2013) 98e101 101of secondarymalignancies of 6%. The patient received the treatment
strategy of R-Hyper-CVAD according to the advice of Dreyling et al,8
and achieved a quick and excellent alleviation of symptoms, as
evident from the skinmanifestation and the level of serum calcium.
However, secondary pneumonia was the direct cause of death.References
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